China makes world's first 5G satellite-to-phone video call. Will it test US TikTok curbs?
The world's first direct 5G satellite-to-smartphone broadband video call by scientists in China has raised new questions about the effectiveness of US restrictions on apps like TikTok.
The technology could theoretically enable streaming video content directly to phones via satellites, however a Chinese expert on 5G standards said that it faced major regulatory, technical, and practical barriers.
The test was carried out earlier this month using a new technology demonstration satellite, according to Liang Baojun, head of China Satellite Network Group (China SatNet). The state-owned company manages the country's planned 13,000-satellite
Guowang internet megaconstellation, which is meant to rival
SpaceX 's
Starlink
'We completed the test based on the 5G Non-Terrestrial Network (NTN) standard, and validated key elements of the integrated space-ground network architecture,' Liang said at the Xiongan BeiDou Ecosystem Cooperation Conference on Saturday in one of his first major public appearances since taking on the role in January. He did not give further details.
11:05
Space race elevates Asia in new world order
Space race elevates Asia in new world order
Adopting the 5G NTN standard meant the phone was connected to the satellite according to internationally recognised 5G specifications – without the need for special hardware – paving the way for future satellite services to work on ordinary smartphones.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
an hour ago
- South China Morning Post
More investor attention coming to China advancements in AI, humanoid tech: Morgan Stanley
China's advancements in artificial intelligence (AI) and humanoid technology will continue to capture the imaginations of investors as the world turns its focus to the region, according to Morgan Stanley 's director of pan-Asia research. Advertisement 'The DeepSeek announcement has shifted the fundamental discussion about China to technological innovation,' said Magdalena Stoklosa in an interview last month. 'This theme is multi-year and incredibly important.' Her team identified technological diffusion and the spread of AI across economies as key long-term research themes. AI start-up DeepSeek's breakthroughs earlier this year in large-language models sparked a rally in Chinese stocks. In February, the US investment bank upgraded Chinese stocks to equal weight from underweight, due to improving valuations and a significant shift towards new-economy companies. 'We still see that China is underweight from a perspective of global emerging markets positioning and it should effectively be at least close,' Stoklosa said. Advertisement Over the next 12 to 18 months, she said it was important to keep an eye on how various AI models work, spread through the economy and become monetised. 'In China, the discussion is layered with government support for AI infrastructure, a thriving innovation scene with start-ups, mega industry players, and a strategic push to build open-source models that make access to AI quicker and more affordable for many corporations,' she added.
South China Morning Post
2 hours ago
- South China Morning Post
China boosts research of Southeast Asian populations overlooked in Human Genome Project
For more than two decades, the Human Genome Project (HGP) – a landmark scientific endeavour led by Western nations – mapped humanity's genetic blueprint, yet the rich diversity of Southeast Asia was overlooked. Despite being home to nearly 300 million people, including the world's largest indigenous population, mainland Southeast Asia (MSEA) contributed a mere 1.57 per cent to global genomic databases, with most data derived from diaspora communities rather than local populations. Chinese researchers say they now aim to rectify the omission. Scientists from the Kunming Institute of Zoology, an affiliate of the Chinese Academy of Sciences, have spearheaded a decade-long collaboration with 34 Southeast Asian research teams, culminating in the first comprehensive genomic atlas of the region – the SEA3K data set – which was published in Nature on May 14. 02:43 Nobel Medicine Prize awarded to US duo for 'fundamentally important' discovery of microRNA Nobel Medicine Prize awarded to US duo for 'fundamentally important' discovery of microRNA The study revealed striking insights, including that MSEA populations harbour unique genetic adaptations to tropical challenges as well as distinct Denisovan ancestry linked to Russia's far east. Before China took a role in the research, fewer than 200 indigenous genomes from MSEA existed in global databases, with neighbouring India contributing most via Southeast Asian diaspora samples, according to the paper. Even city state Singapore, a regional sequencing hub, accounted for 92 per cent of the region's limited data, leaving Cambodia, Laos, Myanmar, Thailand and Vietnam virtually invisible in the genomic era. 'For over a decade, we conducted fieldwork in Southeast Asian rainforests, adhering to local ethical protocols, fostering community engagement and documenting indigenous cultural and linguistic contexts,' corresponding author Su Bing said in an interview with China Science Daily on May 19. Researchers collected samples from Southeast Asian populations covering six countries, five prominent language families and 30 ethnic languages. They completed genome sequencing for 3,023 cases, including 40 high-accuracy long-read sequencing data.
South China Morning Post
2 hours ago
- South China Morning Post
Chinese biotech firm Akeso tumbles on US partner Summit's setback for cancer drug
Chinese biotech firm Akeso, whose cancer drug has been hailed as a breakthrough for the nation's pharmaceutical industry, suffered a setback after less favourable clinical data dashed hopes for a quick US regulatory approval. Advertisement Akeso's shares fell 11.6 per cent to HK$73.65 in the morning session on Monday. US partner Summit Therapeutics' Nasdaq-listed shares slumped 30.5 per cent on Friday to US$18.22, the lowest since April 9. Summit said on Friday that the US Food and Drug Administration (FDA) indicated that a 'statistically significant' benefit on overall survival – from start of treatment to death – was required to support marketing approval for the ivonescimab antibody. Ivonescimab targets non-small cell lung cancer patients whose tumours showed a genetic abnormality that drives unusual cell growth. Akeso is based in Zhongshan in China's southern Guangdong province. Photo: Handout Summit said the first global phase-three clinical trial of Akeso's ivonescimab showed that it was effective in restoring patients' immune systems capabilities to attack tumour cells and slowed tumour progression. But ivonescimab had not yet demonstrated a survival benefit for patients in the study.
